CA2477004C - Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances - Google Patents

Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances Download PDF

Info

Publication number
CA2477004C
CA2477004C CA2477004A CA2477004A CA2477004C CA 2477004 C CA2477004 C CA 2477004C CA 2477004 A CA2477004 A CA 2477004A CA 2477004 A CA2477004 A CA 2477004A CA 2477004 C CA2477004 C CA 2477004C
Authority
CA
Canada
Prior art keywords
hydrocodone
peptide
naltrexone
gly
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2477004A
Other languages
English (en)
French (fr)
Other versions
CA2477004A1 (en
Inventor
Thomas Piccariello
Randal J. Kirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire LLC filed Critical Shire LLC
Priority to CA2740256A priority Critical patent/CA2740256A1/en
Publication of CA2477004A1 publication Critical patent/CA2477004A1/en
Application granted granted Critical
Publication of CA2477004C publication Critical patent/CA2477004C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2477004A 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances Expired - Fee Related CA2477004C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2740256A CA2740256A1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35836802P 2002-02-22 2002-02-22
US60/358,368 2002-02-22
US36208202P 2002-03-07 2002-03-07
US60/362,082 2002-03-07
PCT/US2003/005525 WO2003072046A2 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2740256A Division CA2740256A1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Publications (2)

Publication Number Publication Date
CA2477004A1 CA2477004A1 (en) 2003-09-04
CA2477004C true CA2477004C (en) 2011-05-10

Family

ID=27767540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2477004A Expired - Fee Related CA2477004C (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Country Status (9)

Country Link
US (1) US7622441B2 (https=)
EP (2) EP1531844B1 (https=)
JP (1) JP4878732B2 (https=)
KR (1) KR100822498B1 (https=)
AU (2) AU2003219863C1 (https=)
CA (1) CA2477004C (https=)
ES (1) ES2500117T3 (https=)
IL (2) IL163667A0 (https=)
WO (1) WO2003072046A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20090306228A1 (en) * 2000-11-14 2009-12-10 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) * 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
CN1747737A (zh) * 2003-01-13 2006-03-15 新河药品股份有限公司 糖偶联物防止管制药物的滥用
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MXPA05012850A (es) * 2003-05-29 2006-05-17 New River Pharmaceuticals Inc Compuestos de anfetamina resistentes al abuso.
EP1675555A4 (en) * 2003-09-30 2011-03-09 Shire Llc PHARMACEUTICAL COMPOSITIONS FOR PREVENTING EXCESSIVE DOSE OR ABUSE
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
JP2008519055A (ja) * 2004-11-08 2008-06-05 シャイア エルエルシー ミルタザピンと興奮剤複合物の併用投与の相乗効果
US20060135906A1 (en) * 2004-11-16 2006-06-22 Akihiko Matsumura Iontophoretic device and method for administering immune response-enhancing agents and compositions
JP2006296511A (ja) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc 外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20070083186A1 (en) * 2005-09-30 2007-04-12 Darrick Carter Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
JP2009509676A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 ナノ粒子と接合された活性物質のイオントフォレーシス送達
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
JP2009509677A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 小胞封入活性物質のイオントフォレーシス送達
US7848801B2 (en) * 2005-12-30 2010-12-07 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
CA2653741C (en) * 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
US20080207668A1 (en) * 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
ES2364865T3 (es) 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
EP2123259A1 (en) * 2007-01-16 2009-11-25 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
EP2433655A3 (en) 2007-02-08 2013-05-15 Kempharm, Inc. Homoarginine-prodrugs of amphetamine
US20110105381A2 (en) * 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
JP5489988B2 (ja) * 2007-05-18 2014-05-14 Ｔｔｉ・エルビュー株式会社 有効成分の生体界面への改善された放出を確保する経皮送達装置
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
AR073575A1 (es) * 2008-09-10 2010-11-17 Transcu Ltd Aparato y metodo para dispensar basados en hpc liquidos viscosos en sustratos porosos por ejemplo proceso continuo basado en bandas
ES2414856T3 (es) 2008-12-12 2013-07-23 Paladin Labs Inc. Formulaciones de fármaco narcótico con potencial de adicción disminuido
WO2010078486A2 (en) 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
EP2448408A4 (en) * 2009-07-02 2015-06-03 Kempharm Inc CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
AU2010272233A1 (en) 2009-07-17 2012-02-09 Shire Llc Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
CA2773521C (en) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US20130079364A1 (en) * 2010-04-21 2013-03-28 Signature Therapeutics, Inc. Peripheral Opioid Agonists and Peripheral Opioid Antagonists
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
WO2016043698A1 (en) * 2014-09-15 2016-03-24 Inspirion Delivery Technologies, Llc Orally administrable compositions and methods of deterring abuse by intranasal administration
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
EP3595663A4 (en) * 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTIPLE SUBUNITY OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND ABUSE
WO2019018638A1 (en) 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. PRODRUGS OF EXTENDED RELEASE OPIOID OPIOIDS RESISTANT TO ABUSE
EP3755704A1 (en) 2018-02-23 2020-12-30 Rhodes Technologies Inc. Novel opioid compounds and uses thereof
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
DE1493824A1 (de) * 1964-01-27 1969-05-22 Hoffmann La Roche Verfahren zur Herstellung von Aminocarbonsaeureamiden
CH406567A (de) 1964-02-10 1966-01-31 Inventio Ag Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb
GB1112347A (en) 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US3846399A (en) * 1969-04-10 1974-11-05 Merck & Co Inc Process for controlled stepwise synthesis of polypeptides
US3975342A (en) * 1972-05-15 1976-08-17 Biological Developments, Inc. Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto
US3884898A (en) * 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3843696A (en) 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US3998799A (en) * 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4025501A (en) * 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
GB1592552A (en) * 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4399121A (en) * 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
ATE60340T1 (de) * 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IN165717B (https=) * 1986-08-07 1989-12-23 Battelle Memorial Institute
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5026827A (en) * 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5767227A (en) * 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
EP0477931B1 (en) 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2096495C (en) * 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
IL107400A0 (en) 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
AU5722694A (en) 1993-11-05 1995-05-23 Astra Aktiebolag Novel amino acid derivatives
WO1995014033A1 (en) 1993-11-19 1995-05-26 Aktiebolaget Astra Novel dipeptide derivatives
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5847436A (en) * 1994-03-18 1998-12-08 Kabushiki Kaisha Tokai Rika Denki Seisakusho Bipolar transistor having integrated thermistor shunt
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5910569A (en) * 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5710256A (en) * 1995-04-03 1998-01-20 Biosite Diagnostics Incorporated Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP0831817B1 (en) * 1995-06-07 2001-03-14 Joel K. Swadesh Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
US5851536A (en) 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
DE69735057T2 (de) * 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
GB9606975D0 (en) 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5970477A (en) * 1996-07-15 1999-10-19 Bellsouth Intellectual Property Management Corporation Method and system for allocating costs in a distributed computing network
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
TW460478B (en) * 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
ATE314372T1 (de) 1998-01-29 2006-01-15 Univ Monash Therapeutische verbindungen
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3699000A (en) * 1999-03-10 2000-09-28 Lotus Biochemical Corporation Use of protein conformation for the protection and release of chemical compounds
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001008661A2 (en) * 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US6740641B2 (en) * 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
JP4360906B2 (ja) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法

Also Published As

Publication number Publication date
ES2500117T3 (es) 2014-09-30
EP1531844A4 (en) 2007-06-13
EP2319540A1 (en) 2011-05-11
JP2005524648A (ja) 2005-08-18
AU2003219863B2 (en) 2008-07-31
JP4878732B2 (ja) 2012-02-15
IL163667A (en) 2011-03-31
US20050080012A1 (en) 2005-04-14
AU2003219863C1 (en) 2009-03-05
CA2477004A1 (en) 2003-09-04
WO2003072046A2 (en) 2003-09-04
EP1531844A2 (en) 2005-05-25
WO2003072046A3 (en) 2005-03-10
AU2008229978A1 (en) 2008-11-06
AU2003219863A1 (en) 2003-09-09
EP1531844B1 (en) 2014-08-20
US7622441B2 (en) 2009-11-24
KR100822498B1 (ko) 2008-04-16
AU2008229978B2 (en) 2012-03-22
IL163667A0 (en) 2005-12-18
KR20040095228A (ko) 2004-11-12

Similar Documents

Publication Publication Date Title
CA2477004C (en) Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
JP4691500B2 (ja) 過剰摂取又は乱用を防止するための薬学組成物
US20100144645A1 (en) Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
US7375082B2 (en) Abuse-resistant hydrocodone compounds
US7338939B2 (en) Abuse-resistant hydrocodone compounds
US8343927B2 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2007126832A2 (en) Pharmaceutical compositions for prevention of overdose or abuse
US20070203055A1 (en) Compounds and compositions for prevention of overdose of oxycodone
EP2007762A2 (en) Mono and di-substituted oxycodone compounds and compositions
US20080090771A1 (en) Abuse-resistant hydrocodone compounds, compositions and methods of using the same
CN101437517A (zh) 提高共价结合的化合物的镇痛效果、减少其副作用和防止其滥用的组合物和方法
US20070066537A1 (en) Compounds and compositions for prevention of overdose of oxycodone
CN100413533C (zh) 一种防止管制物质滥用的持续释放的药学化合物
CN1925865B (zh) 防止用药过量或滥用的药物组合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210224